How US kids mental health suffered during Zoom school: A QUARTER of Pre-K-12 students in Chicago were stressed, anxious and angry during remote learning, survey finds
A survey of the caregivers of more than 32,000 Chicago students found that a quarter of them were stressed, anxious and angry amid remote learning
Nearly two-thirds of kids had good peer relationships pre pandemic, but that plunged to less than half of students after schools closed
Rates of anxiety approximately doubled for black and Hispanic children, while rates of anger and agitation nearly tripled
Pediatricians call on schools to not just reopen, but to prepare to help kids readjust to post-pandemic life
Malaria Vaccine Shows Promise--Now Come Tougher Trials scientificamerican.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from scientificamerican.com Daily Mail and Mail on Sunday newspapers.
Apr 22, 2021 12:14pm Prevencio’s HART tests rely on machine learning to analyze blood samples for evidence of obstructive coronary artery disease, Kawasaki disease, the risk of heart attack or stroke, and more. (Pixabay)(Pixabay / PublicDomainPictures)
With high hopes resting on Prevencio’s AI-driven blood tests, it’s only logical that the company would turn to Atlas Genomics to help shoulder the load.
Prevencio tapped Atlas CLIA-certified molecular diagnostic laboratory in Seattle to support the commercial rollout of its HART blood test technology, which can now be ordered for research use. The financial terms of the partnership were not disclosed.
Prevencio develops blood tests that identify cardiovascular diseases and other heart-related risks by using machine learning to parse dozens of protein levels and other biomarkers at once.
Previously approved drugs starting points for COVID-19 therapeutics
Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).
By screening a commercial library of drugs that have already been approved by international regulatory agencies, the team identified more than 50 compounds that demonstrated some efficacy in blocking the initial stage of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of COVID-19.
The compounds were able to disrupt the binding of a surface viral protein called Spike to its host cell receptor angiotensin-converting enzyme 2 (ACE2).